TOKYO, March 9, 2020 /PRNewswire/ -- FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with the development and production of their biologics, vaccines and gene therapies, announced today that Steve Bagshaw, chief executive officer of FDB, has decided to retire from his current position, effective April 1, 2020. Bagshaw will continue with the company in the role of non-executive Chairman.
Martin Meeson has been appointed by the FDB Executive Committee to succeed Steve Bagshaw as chief executive officer. Presently Meeson serves as president & chief operating officer of FUJIFILM Diosynth Biotechnologies, U.S.A., Inc. Bagshaw, in his role of non-executive chairman, will assist with the transition in executive leadership.
As an accomplished industry executive, Meeson has played a key role in the incredible growth and success of FDB. Meeson's tenure at FDB began in 2008 when he joined the company as director of finance, IT and supply chain for the United Kingdom site. In 2013 he moved to the North Carolina site as senior vice president of global finance. During this period, he was closely involved in the acquisition FDB's Texas facility. He was named president and chief operating officer of the US operations on April 1, 2015. In this role Meeson has spearheaded the company's long term gene therapy growth strategy and driven significant investment for expansion at both the North Carolina and Texas facilities.
Before joining FDB, Meeson was finance director at Oxford Chemicals where he was responsible for all aspects of finance, IT, and purchasing. He has also held leadership positions at Hibernia Foods, ICI/DuPont and KPMG.
"FDB has an exciting future ahead. I am delighted to see Martin take on the role of chief executive officer to lead the organization in its future growth" said Steve Bagshaw. "Martin has the skill set and experience to work with all of the FDB teams and our partners across the world to continue to deliver on our mission to advance tomorrow's medicines."
"I am honored to be appointed to lead FDB at these exciting times," said Martin Meeson, "I look forward to continue to work with the people and the partners that we have here at FDB. The mission that we share has been what has motivated me to be such a significant part of the leadership of this organization over the last few years. Exciting times are ahead and the strength and energy of the people we have around us will continue to build our success as we move forward."
FUJIFILM Diosynth Biotechnologies an industry-leading Biologics Contract Development and Manufacturing Organization (CDMO) with locations in Teesside, UK, RTP, North Carolina, College Station, Texas and Hillerod, Denmark. FUJIFILM Diosynth Biotechnologies has over thirty years of experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules, viral products and medical countermeasures expressed in a wide array of microbial, mammalian, and host/virus systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ microbial and Apollo™ X cell line systems to process development, analytical development, clinical and FDA-approved commercial manufacturing. FUJIFILM Diosynth Biotechnologies is a partnership between FUJIFILM Corporation and Mitsubishi Corporation. For more information, go to: www.fujifilmdiosynth.com
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2019, the company had global revenues of $22 billion, at an exchange rate of 111 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.
SOURCE FUJIFILM Diosynth Biotechnologies